Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Liver Neoplasms 2Carcinoma, Hepatocellular 2Pituitary Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Nelson Syndrome 1Lymphoma, Follicular 1Hypoglycemia 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

TH 302 2pasireotide 1omburtamab I-131 1gallium Ga 68 dotatate 1entinostat 1Thalidomide 1Sunitinib 1Radiotherapy, Image-Guided 1Nivolumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × pasireotide × Gastrointestinal × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡